ABSTRACT Background. For rectal cancer patients who have already survived a period of time after diagnosis, survival probability changes and is more accurately depicted by conditional survival. The specific aim of this study was to develop an interactive tool for individualized estimation of changing prognosis for rectal cancer patients. Methods. A multivariate Cox proportional hazards (CPH) survival model was constructed using data from rectal cancer patients diagnosed from 1994 to 2003 from the Surveillance, Epidemiology, and End Results (SEER) database. Age, race, sex, and stage were used as covariates in the survival prediction model. The primary outcome variable was overall survival conditional on having survived up to 5 years from diagnosis. Results. Data from 42,830 rectal cancer patients met the inclusion criteria. The multivariate CPH model showed age, race, sex, and stage as significant independent predictors of survival. The survival prediction model demonstrated good calibration and discrimination, with a bootstrap-corrected concordance index of 0.75. A webbased prediction tool was built from this regression model that can compute individualized estimates of changing prognosis over time.
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Conclusions. An interactive prediction modeling tool can estimate prognosis for rectal cancer patients who have already survived a period of time after diagnosis and treatment. Having more accurate prognostic information can empower both patients and clinicians to be able to make more appropriate decisions regarding follow-up, surveillance testing, and future treatment.
A cancer patient's prognosis is often based on aggregate data from large heterogeneous groups of patients in the published oncology literature, and these estimates are usually only made at the time of diagnosis. Survival probability however, changes over time for cancer patients, and estimates of prognosis made at the time of diagnosis are no longer applicable after a patient has already survived for a period after diagnosis and treatment. 1 Conditional survival (CS) is a more accurate estimate of prognosis for these cancer survivors because it accounts for the continuously changing hazard rates over time. 2, 3 CS estimates can be helpful for patients and providers who seek more accurate prognostic estimates to help guide health-related decisions. This information enables cancer survivors to more accurately assess whether their prognosis is improving or declining over time. It can also be used by providers to determine more appropriate therapy and follow-up surveillance testing.
Several authors have published studies on CS for breast, colon, central nervous system (CNS), lung, head and neck, and other advanced carcinomas. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] We have also previously published our work on CS for various disease sites, including breast, head and neck, gynecologic, gastrointestinal, and other malignancies.
retroperitoneal location in the low pelvis. To date, there have been no prediction models available to specifically depict or predict how prognosis changes for rectal cancer patients after they have survived a time interval after diagnosis and treatment. Such individualized prognostic information is extremely valuable to both patients and providers.
In our previous work, we demonstrated how conditional survival changes over time for rectal cancer patients using basic Kaplan-Meier survival analyses. 25 In this follow-up study, we constructed a Cox proportional hazards survival regression model from these data to enable estimation for individual patients. Using this regression model, we built an interactive web-based prediction tool that can provide customized conditional survival predictions for rectal cancer patients who have already survived a period of time following their diagnosis and treatment.
METHODS
CS is derived from the concept of conditional probability in biostatistics. CS can be calculated from traditional Kaplan-Meier or actuarial life table survival data. The mathematical definition of CS can be expressed as follows: CS(y|x), is the probability of surviving an additional y years, given that the person has already survived x years. 1 Let S(t) be the traditional actuarial life table survival at time t. CS can be expressed as:
For example, to compute the 5-year CS for a patient that has already survived 2 years, the survival at 5 ? 2 years, S (7), is divided by the survival at 2 years, S(2). When a survival curve has a changing hazard rate over time, this will be reflected as a change in CS as more time elapses from the time of diagnosis.
The Surveillance, Epidemiology, and End Results (SEER 17) database from the National Cancer Institute is a population-based cancer registry covering approximately 26% of the U.S. population across several disparate geographic regions and is the largest publicly available domestic cancer dataset. 40 SEER program registries collect data on patient demographics, cancer type and stage, first course of treatment, and follow-up vital status. We ana- A Cox proportional hazards (CPH) multivariate regression model was constructed using these data. The primary outcome variable was overall survival, conditional upon 0-5 years already survived. Covariates included in the model were age, race (white, black, Asian/Pacific Islander, Alaskan/American Indian), sex, and stage (AJCC TNM 3rd edition). All covariates were treated as discrete and converted to binary variables, except for age, which was modeled as a continuous variable and fitted to a smoothed restricted cubic spline function as per Harrell 42 The model was internally validated for both discrimination and calibration using bootstrap correction with 100 resamples.
The CPH regression model was incorporated into a webbrowser based software application. Using this tool, users can enter specific tumor and patient characteristics, and the system will calculate a customized conditional survival curve specific to that individual patient. This software tool was built using JavaScript.
This research study was determined to be exempt from requiring institutional review board approval by the authors' home institution.
RESULTS
A total of 42,380 rectal cancer patients were included in the analysis. Numbers of patients in each stage according to sex, age, and race are shown in Table 1 . The 10-year actuarial survival data (Fig. 1) were used to calculate 5-year observed CS in categories of stage, age, gender, and race. Although higher-stage patients had lower CS overall at diagnosis compared with lower-stage patients, higher- Age was modeled using a restricted cubic spine function, which yields an effective hazard ratio that varies continuously with age stage patients had greater increases in CS as more time elapsed from diagnosis ( Fig. 2) . As the time survived since diagnosis increased from 0 to 5 years, the 5-year observed conditional survival for stage I patients increased minimally from 71% to 74%, while CS for stage II increased from 55% to 67%. Stage III increased from 50% to 66%, and stage IV increased from 7% to 53%. Patients aged 65 years and over at diagnosis had lower CS than those under 65 years, both at diagnosis (44.3% vs 65.7%) and at 5 years from diagnosis (60.3% vs 82.1%). For all stages of disease, men had slightly lower 5-year survival than women, both at diagnosis (52.0% vs 55.1%) and after 5 years (69.9% vs 72.1%). The largest differences by sex were in stage IV patients. Among race, the largest disparities were in stage IV disease, with African American patients having lower CS compared with white and ''other'' patients, particularly with longer time intervals from diagnosis. A CPH model was built from these data using age, race, sex, and stage as covariates. The beta coefficients for the CPH model are shown in Table 2 . All covariates were found to be statistically significant prognostic factors in this multivariate analysis. The C-index for discrimination for this CPH model was 0.75. The calibration curve showed good agreement between predicted and observed outcomes. Figure 3 shows a screenshot of the interactive webbased prediction tool that was built from the CPH survival model. The user enters specific information about a rectal cancer patient, including time already survived since diagnosis. The tool will then estimate the percent likelihood the patient will survive up to an additional 5 years from that time. The interactive nature of the tool allows the user to see how a patient's prognosis often improves with additional time survived since diagnosis. This web-based prediction tool is available for public use and can be found at http://skynet.ohsu.edu/nomograms.
DISCUSSION
Conditional survival quantifies changes in prognosis as time progresses from diagnosis. With this interactive webbased tool, patients and providers will have the ability to more accurately quantify changes in prognosis over time. This information is potentially of great interest to patients, clinicians, and researchers. Patients should be given an accurate risk assessment and prognosis that accounts for time already survived since diagnosis. Clinicians could also use this tool to implement a more evidence-driven approach to planning posttherapy surveillance, based on a patient's changing risk. Physicians often arbitrarily taper follow-up visit frequency after 2-3 years, but it may be more appropriate to schedule follow-up testing frequency and duration based on an individual patient's actual disease risk, rather than based on generalized guidelines.
Conditional survival may also assist in detecting differences in subgroup survival patterns. 8, 14 In other studies of CS, it has been found that patients with poorer initial prognoses exhibit the greatest increases in CS as they survive for longer periods of time from diagnosis. 4, 8, 11, 12 Our analysis indicates that this is also true for rectal cancer, with CS appearing to increase most for patients older than 65 years of age and those with advanced-stage disease.
Although CS generally increased over time for all patient groups examined in this study, CS increases are not necessarily observed for all cancer types. In analyses of disease at other sites, a CS decline has been observed for certain population subsets, such as the elderly, patients with unfavorable tumor histology, and those with poor performance status. 11, 12, 31 Consequently, CS trends over time cannot be predicted from point estimates made at the time of diagnosis. A full Kaplan-Meier survival plot must be examined in order to determine the trend of CS over time; in essence, the shape of the Kaplan-Meier plot influences whether CS increases or decreases over time. CS quantifies prognostic changes over time in a manner readily comprehended by both providers and patients.
There are several limitations to this study. Treatment data in SEER are limited (i.e., no chemotherapy regimen or radiotherapy dose is recorded), so we did not attempt a subanalysis by treatment modality. In addition, some subgroups had small sample size, which precludes our ability to make more definite generalizations regarding the observed differences between some subgroups. Since SEER does not include information on disease recurrence, and since cause of death information is not always reliable, we are unable to analyze other important end points, such as time to recurrence and disease-free survival. Finally, historic survival data collected over an extended period of time may not reflect current practices in oncology. Despite these limitations, however, the SEER dataset is the largest population-based cancer registry in the United States, and it allows us to make reasonable estimates of CS that are generally applicable for most patients with rectal cancer.
Conditional survival data and this prediction calculator should be considered within the individual context of patient care. Although CS provides a more accurate quantification of prognosis for long-term survivors, it is important that this tool be used in combination with other factors that may influence mortality risk that may not be accounted for in this model.
In conclusion, conditional survival is a method for quantifying a changing risk profile in terms that are meaningful and easily understood by patients and providers. We have constructed a prediction model that estimates conditional survival for rectal cancer patients. This webbased interactive prediction tool can be used by patients and providers to make individualized estimates of updated prognosis for patients who have already survived from 1 to 5 years after diagnosis. We believe that more accurate estimation of CS will permit improved risk assessment and follow-up care for rectal cancer survivors. CONTRIBUTIONS SJW, JYL, CDF, JKC, and CRT carried out the conception and design of this study. SJW and AWS coordinated the collection and assembly of data. SJW, AWS, CDF, and JKC participated in data analysis and interpretation. SJW, AWS, JYL, and CDF each helped draft the manuscript. SJW and CRT provided final approval of the manuscript.
